Baronsmead

Baronsmead Venture Trust plc

Half-yearly report for the six months ended 31 March 2025



About Baronsmead Venture Trust plc

Our investment objective

Baronsmead Venture Trust plc (the "Company") is a tax efficient listed company which aims to achieve long-term positive investment returns for private investors, including tax-free dividends.

Investment policy¹

- To invest primarily in a diverse portfolio of UK growth businesses, whether unquoted or traded on the Alternative Investment Market ("AIM").
- Investments are made selectively across a range of sectors in companies that have the potential to grow and enhance their value.

Key elements of the business model

Access to an attractive, diverse portfolio

The Company gives shareholders access to a diverse portfolio of growth businesses.

The Company will make investments in growth businesses, whether unquoted or traded on AIM, which are substantially based in the UK in accordance with the prevailing VCT legislation. Investments are made selectively across a range of sectors.

The Manager's approach to investing

The Manager endeavours to select the best opportunities and applies a distinctive selection criteria based on:

- Primarily investing in parts of the economy which are experiencing long term structural growth.
- Businesses that demonstrate, or have the potential for, market leadership in their niche.
- Management teams that can develop and deliver profitable and sustainable growth.
- Companies with the potential to become an attractive asset appealing to a range of buyers at the appropriate time to sell.

In order to ensure a strong pipeline of opportunities, the Manager invests in building deep sector knowledge and networks and undertakes significant proactive marketing to target companies in preferred sectors. This approach generates a network of potentially suitable businesses with which the Manager maintains a relationship ahead of possible investment opportunities.

Dividend policy²

- The Board will, wherever possible, seek to pay two dividends to shareholders in each financial year, typically an interim dividend in September and a final dividend following the Annual General Meeting in February/March.
- The Board will use, as a guide, when setting the dividends for a financial year, a sum representing 7 per cent of the opening net asset value of that financial year.

1. This is a summary of the Company's investment policy that is set out on page 2 of the Company's Annual Report and Financial Statements for the year ended 30 September 2024.

2. This is a summary of the Company's dividend policy that is set out on page 2 of the Company's Annual Report and Financial Statements for the year ended 30 September 2024.

The Manager as an influential shareholder

The Manager is an engaged and supportive shareholder (on behalf of the Company) in both unquoted and significant quoted investments.

For unquoted investments, representatives of the Manager often join the investee board.

The role of the Manager with investees is to ensure that strategy is clear, the business plan can be implemented and the management resources are in place to deliver profitable growth. The aim is to build on the business model and grow the company into an attractive target which can be sold or potentially floated in the medium term.

A more detailed explanation of how the business model is applied is provided in the Other Matters section of the Strategic Report on pages 28 to 31 in the Company's Annual Report and Financial Statements for the year ended 30 September 2024.

Contents

01 Strategic report	
Financial highlights	3
Performance summary	4
Chair's statement	6
Investments in the period	10
Realisations in the period	11
02 Statement of Directors' responsibilities Responsibility statement of the Directors in respect of the half-yearly report	13
03 Financial Statements	
Condensed income statement	15
Condensed statement of changes in equity	16
Condensed balance sheet	17
Statement of cash flows	18
Notes to the financial statements	19

If you have sold or otherwise transferred all of your shares in Baronsmead Venture Trust plc, please forward this document and the accompanying form of proxy as soon as possible to the purchaser or transferee, or to the stockbroker, bank or other agent through whom the sale or transfer was, or is being, effected, for delivery to the purchaser or transferee.

04	
Appendices	
Cash returned to shareholders	25
Full investment portfolio	26
Glossary	29
05 Information	
Shareholder information and contact details	31
Corporate information	34

Financial highlights

Net asset value total return¹ (as at 31 March 2025)

394.1p




Net Asset Value ("NAV") total return to shareholders for every 100.0p invested at launch (April 1998).

Funds raised

(six months to 31 March 2025)

Mar 24 £20.3mn



Six months to March Twelve months to September

£20.3mn raised in the period (before costs); and a further £4.7mn raised (before costs) since the period end.

1. Alternative Performance Measures ("APM")/Key Performance Indicators ("KPIs") – please refer to glossary on page 29 for definitions. 2. Please refer to table on page 6 for breakdown of NAV per share movement. 3. Direct investments only - please refer to glossary on page 29 for definitions.

Strategic report

01 Strategic report

Change in net asset value per share^{1,2} (six months to 31 March 2025)

-6.4%



NAV per share decreased 6.4 per cent to 49.4p, before the deduction of dividends, in the six months to 31 March 2025.

New investments³ (six months to 31 March 2025)

£3.6mn



Six months to March Twelve months to September


Investments made into two new and nine follow-on opportunities during the period. (Unquoted: £2.8mn, Quoted: £0.8mn).

Half-yearly report for the six months ended 31 March 2025

3

Performance summary


Ten-year performance record



* Net asset value total return (gross dividends reinvested) rebased to 100p. Source: Gresham House Asset Management Ltd

[‡] Six months to 31 March 2025.

[†] Net asset value increase following the merger of Baronsmead VCT plc & Baronsmead VCT2 plc in February 2016.




Dividend yield since financial year 2019[#]


[#] Prior to financial year 2019, the dividend policy was to maintain a minimum annual dividend level of around 6.5p per share. Source: Gresham House Asset Management Ltd.


NAV cumulative returns to shareholders by date of investment

The chart below shows the NAV cumulative returns to shareholders from £100,000 invested.#



[#] Details of only the first allotment from each fundraising is shown on the chart. * Includes interim dividend of 1.75p per share payable on 8 September 2025.





Investment diversification at 31 March 2025 by value

Chair's statement

The decline of 3.4p per share (6.4 per cent) in the Company's net asset value (NAV) over the six months to 31 March 2025 to 49.4p per share, though disappointing, was not representative of the underlying resilience of many of the Company's investee companies. This can be seen in the recovery in the value of many of the listed investments after the period end and the increase in NAV to 51.9p per share by 31 May 2025.

The inauguration of President Trump in January of this year has heralded a period of heightened global economic and political uncertainty. Additionally, global financial markets reacted to the prospect of global trade disputes. Consequently, the Company's NAV declined by 2.8p per share in the 3 months to 31 March 2025, being 82 per cent of the decline in NAV over the period under review with further detail on this set out in the section below.

It is likely that further macroeconomic and geopolitical headwinds will continue. However, your Board continues to believe that, in aggregate, the fundamentals of the underlying portfolio companies are still robust and the Company's investment policy of having a combination of unquoted and listed assets support a more consistent total return to shareholders over the medium to long term. Having said that, it is in the nature of VCT qualifying investments that some portfolio companies will continue to require more capital to scale and generate value. In addition, the Board is working with the Manager to continue its focus on improving and sustaining unquoted performance which we know has been an issue for shareholders. The Board is alert to wider issues around performance fees in the VCT sector over the last twelve months.



Results

During the six months to 31 March 2025, the Company's NAV per share decreased 6.4 per cent from 52.8p to 49.4p after the payment of the final dividend of 2.0p per share on 17 March 2025. Between 31 December 2024 and 31 March 2025, the Company's net asset value (NAV) declined 2.8p per share from 52.2p per share to 49.4p per share. This representing 82 per cent of the 3.4p per share decline in the Company's NAV over the 6 months to 31 March 2025.

The table below breaks down the guarterly movement in NAV over the 6 months to 31 March 2025.

	Pence per ordinary share
NAV as at 1 October 2024	
(after deducting the final dividend of 2.0p)	52.8
Valuation decrease (1.1 per cent)	(0.6)
NAV as at 31 December 2024 (after deducting the final dividend of 2.0p)	52.2
Valuation decrease (5.3 per cent)	(2.8)
NAV as at 31 March 2025	49.4

Dividends

The Board has declared an interim dividend of 1.75p per share to be paid on 8 September 2025 to shareholders on the register as of 8 August 2025. The Board is aware that dividends are an important part of the total return to the shareholders' investment in the Company. As such, the Board is aiming to achieve its dividend policy objective of an annual yield of 7.0 per cent based on the NAV at the beginning of the financial year. I must of course remind shareholders this is not a guarantee and that payment dates and the amount of future dividends depend on the level and timing of profitable realisations.

Portfolio review

The table below provides a summary of each asset class and the return generated during the period under review.

Asset class	NAV* (£mn)	% of NAV*	Number of investee companies	% return in the period [‡]
Unquoted	53	27	47	(O)
AIM-traded companies	59	30	40	(13)
WS Gresham House Equity Funds [†]	59	31	74	(6)
Liquid assets#	24	12	N/A	2
Total	195	100	161	(6)

- By value at 31 March 2025.
- Return includes interest received on unquoted realisations during the period
- Excludes investee companies with holdings by more than one fund.
- [#] Represents cash, OEICs and net current assets. % return in the period relates only to the cash liquidity funds.

The value of the unquoted portfolio remained flat for the six months to 31 March 2025. 35 per cent of the portfolio registered an increase in value during the period, 35 per cent remained flat and 30 per cent registered reductions in value. The main drivers of positive movements in value were the investments in CitySwift and Panthera Biopartners, with both showing good trading momentum and increases in revenue during the period. The main detractors from performance were the investments in Orri, despite further funding, and Huma Therapeutics, with both facing difficult trading conditions and reduced revenues. The Manager continues to focus on improving and sustaining unquoted performance.

The value of the Company's portfolio of investments directly held in AIM-traded companies decreased 12.8 per cent in the six months to 31 March 2025. The value of the Company's investments into the WS Gresham House UK Micro Cap Fund decreased by 3.5 per cent and the WS Gresham House UK Smaller Companies Fund decreased by 8.9 per cent compared to the IA UK Smaller Companies sector which decreased by 9.1 per cent. The Company's investment in the WS Gresham House UK Multi Cap Income Fund decreased by 9.4 per cent in the period compared to the IA UK Equity Income sector that decreased by 0.1 per cent. This was as a result of the volatility of global financial markets since the beginning of the year as well as some domestic issues such as the increase in employers' national insurance contributions. It is encouraging to note, however, that during the period, over 80 per cent of the trading update announcements made by companies within the WS Gresham House Equity Funds portfolios were either in line or ahead of expectations.

Despite the continued volatility in listed markets experienced immediately after the period end, I am pleased to report that after that the Company's portfolio of AIM traded companies increased by 4.7 per cent in the month to 30 April 2025. This was subsequently followed up with a further increase of 5.9 per cent in the month to 31 May 2025.

Investments

In the six months to 31 March 2025, the Company made two new unquoted investments totalling £1.5mn and nine followon investments with a combined value of £2.1mn as follows:

- Mobility Mojo (unquoted) a disability access assessment platform (£0.5mn)
- Much Better Adventures (unquoted) a marketplace offering exclusive guided and bespoke global travel experiences (£0.5mn)

The Company also made nine follow-on investments with a combined value of £2.1m during the period under review.

Realisations

In the listed portfolio, the Manager continued to take profits from partial sales of the Company's holdings of Cerillion and SEEEN resulting in proceeds of £0.1mn and £0.2mn respectively, and gross money multiples of 25.7x and 0.2x of original cost. There were also partial realisations of MXC Capital, following a tender offer, and Crossword Cybersecurity following it entering administration during the period.

There were no realisations in the unquoted portfolio during the period.

Fundraising

In the 2024/25 tax year, the Company successfully raised £20.3mn (before costs) through an offer for subscription. The Board decided to extend the offer into the 2025/26 tax year in April 2025 with a further £0.9mn being allotted on 1 May 2025 and an additional £3.8mn having been subscribed since then. A fourth and final allotment is expected to take place on or around 3 July 2025. The Directors want to welcome the 803 new shareholders who invested for the first time and also thank the 560 existing shareholders who continue to support the Company.

The Board will consider whether to raise additional funds in the 2025/26 tax year. This will be determined by the Company's cashflow, the overall balance of the Company's portfolio, and its anticipated requirements and opportunities to fund new and follow-on investments over the next two to three years. The Board appreciates that shareholders would like plenty of notice of its fundraising intentions and will ensure that shareholders are informed of the Board's intention to raise new funds, as soon as it becomes practical.

Succession planning

Isabel Dolan stepped down from the Board in January 2025. The Board would like to thank her for her support and insight as the Chair of the Company's Audit Committee and wish her every success for the future.

Following a comprehensive search, I am pleased to inform shareholders that immediately following the period end the Company announced the appointment of two new directors. David Melvin brings a wealth of experience with over 30 years in investment banking and private equity and will take over the role of Chair of the Audit Committee.

Mandeep Singh is an experienced founder, CEO, Non-Executive Director, and investor with expertise, and a proven track record, in scaling tech businesses.

Share price discount and buy back policies

The Board intends to continue with the policy of seeking to maintain a share price discount to NAV of 5 per cent and to buy back shares at that level from time to time with the objective of maintaining liquidity in the market for its existing shares. To that end it will also sell shares out of Treasury in certain circumstances. The day-today management of these policies is undertaken by the Manager on behalf of the Board and are subject to the prevailing market circumstances and on the basis that the Company has adequate resources to make new and followon investments and pay dividends to shareholders.

Outlook

The period since 31 March has seen the implementation of many of the policies brought in by the new Labour government in the Autumn Budget which, together with the almost daily developments regarding the imposition and then retraction of trade tariffs by the US Government has created much uncertainty and global financial volatility.

Whilst the ever-changing landscape makes it very hard to predict the implications for the medium to long term, the immediate impact is highly volatile financial markets and material uncertainty. Unsurprisingly, consumer and business confidence both domestically and globally is likely to have been materially damaged and could take a significant amount of time to repair. The Board expects that this elevated macroeconomic and geopolitical uncertainty will continue to impact our investments beyond the risks that would normally be associated with investing in smaller companies. Added to this, the exit environment remains subdued in comparison to recent years.



However, as outlined above the Company's portfolio remains highly diversified and the hybrid nature of our investment portfolio helps to mitigate those uncertainties. In addition, it is largely positioned in sectors which the Manager expects to provide long-term growth potential operating as many of them do in the UK domestic market.

We remain committed to investing through the economic cycle as experience suggests that this can produce superior returns over the longer term. This can also provide an opportunity for the Company to make high quality investments and build strategic stakes in businesses with exciting potential at good prices. This applies to both new investments and follow-on investments in the portfolio. The Manager continues to see a good pipeline of potential investments and we remain confident that the Manager is suitably positioned to provide the necessary levels of support to the portfolio companies and remains focused on retaining, recovering and helping to grow value in existing and future investee companies.

Fiona Miller Smith Chair

10 June 2025

Investments in the period

Company	Location	Sector	Activity	Book cost £'000
Unquoted investments				
New				
Gentianes Solutions Ltd (trading as Much Better Adventures)	Bristol	Consumer markets	Adventure travel marketplace	1,052
Mobility Mojo (UK) Ltd	Dublin	Technology	Provider of software to evaluate the accessibility of building environments	459
Follow-on				
SecureCloud+ Ltd	Berkshire	Technology	Defence and public sector IT systems	470
Orri Ltd	London	Healthcare & education	Provider of intensive day care treatments for eating disorders	249
Branchspace Ltd	London	Technology	Specialist digital retailing consultancy and software provider to the aviation and travel industry	220
RevLifter Ltd	London	Technology	Al platform using advanced behavioural analytics to deliver tailored promotions to users	168
Counting Ltd	London	Business services	Banking and accounting software for small businesses	117
Focal Point Positioning Ltd	Cambridgeshire	Technology	Research and development focused technology business focusing on global navigation and satellite systems	90
Total unquoted investments				2,825
AIM-traded investments				
Follow-on				
IXICO plc	London	Healthcare & education	Provides technology enabled services to the biopharmaceutical industry worldwide	473
SEEEN plc#	London	Technology	A video technology business	148
Oberon Investments Group plc	London	Business services	Wealth advisory service for individuals and businesses	146
Total AIM-traded investments				767
Total investments in the period*				3,592

Investment into unquoted convertible loan note

* Includes unquoted and AIM investments only

Realisations in the period

Company		First investment date	Original book cost [#] £'000	Proceeds [‡] £'000	Overall multiple return (x)	IRR (%)
Unquoted realisations						
MXC Capital Ltd	Tender offer	May 15	52	24	0.5	_
Total unquoted realisations			52	24		
AIM-traded realisations						
SEEEN plc	Market sale	Sep 19	716	176	0.2	_
Cerillion plc	Market sale	Nov 15	2	44	25.7	41.3
Crossword Cybersecurity plc*	Written off	July 21	2,144	-	_	_
Total AIM-traded realisations			2,862	220		
Total realisations in the period**			2,914	244		

[#] Residual book cost at realisation date.

⁺ Proceeds at time of realisation including interest.

* Only equity written off. Convertible loan note still held.

** Includes unquoted and AIM investments only.



Statement of Directors' responsibilities

Responsibility statement of the Directors in respect of the half-yearly report

Half-yearly report

The important events that have occurred during the period under review, the key factors influencing the financial statements and the principal uncertainties for the remaining six months of the financial year are set out in the Chair's statement and the Strategic report.

The principal risks facing the Company are unchanged since the date of the Company's Annual Report for the financial year ended 30 September 2024 and continue to be as set out in that Report on pages 22 and 23.

Risks faced by the Company include but are not limited to; loss of approval as a Venture Capital Trust, legislative risk, investment performance risk, risk of economic, political and other external factors, regulatory and compliance risk and operational risk. The Board considers the conflicts in Ukraine and the Middle East to be factors which permeate these risks, and their impacts for the remaining six months of the year continue to be kept under review.

Responsibility statement

Each Director confirms that to the best of their knowledge:

- the condensed set of financial statements has been prepared in accordance with FRS 104 Interim Financial Reporting Standards and gives a true and fair view of the assets, liabilities, financial position and profit or loss of the Company.
- This half-yearly report includes a fair review of the information required by:
- a) DTR 4.2.7R of the Disclosure Guidance and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and
- b) DTR 4.2.8R of the Disclosure Guidance and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the Company during that period; and any changes in the related party transactions described in the last annual report that could do so.

The half-yearly report was approved by the Board of Directors on 10 June 2025 and was signed on its behalf by Ms Fiona Miller Smith, Chair.

Fiona Miller Smith

Chair

10 June 2025

Condensed income statement

For the six months to 31 March 2025 (Unaudited)

		Six months to 31 March 2025		Six months to 31 March 2024		Year to 30 September 2024				
	Notes	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000
(Losses)/gains on investments	5	-	(13,492)	(13,492)	_	7,423	7,423	_	14,023	14,023
Income		1,799	-	1,799	2,051	-	2,051	3,572	_	3,572
Investment management fee		(444)	(1,330)	(1,774)	(417)	(1,250)	(1,667)	(900)	(2,699)	(3,599)
Other expenses		(360)	-	(360)	(383)	_	(383)	(701)	_	(701)
Profit/(loss) before taxation		995	(14,822)	(13,827)	1,251	6,173	7,424	1,971	11,324	13,295
Taxation		-	-	-	-	_	_	_	_	_
Profit/(loss) for the period, being the total comprehensive income for the period		995	(14,822)	(13,827)	1,251	6,173	7,424	1,971	11,324	13,295
Return per ordinary share:										
Basic and diluted	2	0.26p	(3.83p)	(3.57p)	0.35p	1.72p	2.07p	0.53p	3.03p	3.56p

All items in the above statement derive from continuing operations.

There are no recognised gains and losses other than those disclosed in the Income Statement.

The revenue column of the Income Statement includes all income and expenses. The capital column accounts for the realised and unrealised profit or loss on investments and the proportion of the management fee charged to capital.

The total column of this statement is the unaudited Statement of Total Comprehensive Income of the Company prepared in accordance with the Financial Reporting Standard ("FRS"). The supplementary revenue return and capital return columns are prepared in accordance with the Statement of Recommended Practice issued by the Association of Investment Companies ("AIC SORP").

Financial **Statements**

03

Condensed statement of changes in equity

For the six months to 31 March 2025 (Unaudited)

	Non-distributable reserves			Distributabl		
	Called-up share capital £'000	Share premium £'000	Revaluation reserve £'000	Capital reserve* £'000	Revenue reserve £'000	Total £'000
At 1 October 2024	42,446	20,036	30,853	115,215	3,633	212,183
(Loss)/profit after taxation	-	-	(10,920)	(3,902)	995	(13,827)
Net proceeds of share issues, share buybacks & sale of shares from treasury	1,627	6,804	-	(4,128)	_	4,303
Dividends paid	-	-	-	(6,506)	(1,148)	(7,654)
At 31 March 2025	44,073	26,840	19,933	100,679	3,480	195,005

For the six months to 31 March 2024 (Unaudited)

	Non-dis	stributable re	eserves	Distributable		
	Called-up share capital £'000	Share premium £'000	Revaluation reserve £'000	Capital reserve* £'000	Revenue reserve £'000	Total £'000
At 1 October 2023	38,162	-	20,357	133,959	2,414	194,892
Profit after taxation	-	-	5,358	815	1,251	7,424
Net proceeds of share issues, share buybacks & sale of shares from treasury	4,284	20,036	_	(2,037)	_	22,283
Dividends paid	-	-	-	(8,749)	(364)	(9,113)
Share premium cancellation costs	-	-	-	(4)	-	(4)
At 31 March 2024	42,446	20,036	25,715	123,984	3,301	215,482

For the year ended 30 September 2024 (Audited)

	Non-distributable reserves			Distributabl		
	Called-up	0			5	
	share	Share	Revaluation	Capital	Revenue	
	capital	premium	reserve	reserve*	reserve	Total
	£'000	£'000	£'000	£'000	£'000	£'000
At 1 October 2023	38,162	-	20,357	133,959	2,414	194,892
Profit after taxation	-	-	10,496	828	1,971	13,295
Net proceeds of share issues, share						
buybacks & sale of shares from treasury	4,284	20,036	-	(4,414)	-	19,906
Dividends paid	_	_	_	(15,154)	(752)	(15,906)
Share Premium cancellation costs	-	-	-	(4)	-	(4)
At 30 September 2024	42,446	20,036	30,853	115,215	3,633	212,183

* Of the distributable reserves noted above £52,069,000 (September 2024: £52,069,000 March 2024: £79,384,000) is not available for dividend distribution due to HMRC VCT rules.

Condensed balance sheet

As at 31 March 2025 (Unaudited)

		As at 31 March 2025	As at 31 March 2024	As at 30 September 2024
	Notes	£'000	£'000	£'000
Fixed assets				
Unquoted investments	5	53,411	51,050	51,226
Traded on AIM	5	58,332	62,336	65,966
Collective investment vehicles	5	83,084	91,445	95,060
Investments	5	194,827	204,831	212,252
Current assets				
Debtors		524	11,574	463
Cash at bank and on deposit		691	649	752
		1,215	12,223	1,215
Creditors (amounts falling due within one year)		(1,037)	(1,572)	(1,284)
Net current assets/(liabilities)		178	10,651	(69)
Net assets		195,005	215,482	212,183
Capital and reserves				
Called-up share capital	3	44,073	42,446	42,446
Share premium		26,840	20,036	20,036
Capital reserve		100,679	123,984	115,215
Revaluation reserve	5	19,933	25,715	30,853
Revenue reserve		3,480	3,301	3,633
Equity shareholders' funds		195,005	215,482	212,183
Net asset value per share		49.35p	55.07p	54.84p
Number of ordinary shares in circulation		395,120,875	391,292,410	386,878,657

		As at 31 March 2025	As at 31 March 2024	As at 30 September 2024
	Notes	£'000	£'000	£'000
Fixed assets				
Unquoted investments	5	53,411	51,050	51,226
Traded on AIM	5	58,332	62,336	65,966
Collective investment vehicles	5	83,084	91,445	95,060
Investments	5	194,827	204,831	212,252
Current assets				
Debtors		524	11,574	463
Cash at bank and on deposit		691	649	752
		1,215	12,223	1,215
Creditors (amounts falling due within one year)		(1,037)	(1,572)	(1,284)
Net current assets/(liabilities)		178	10,651	(69)
Net assets		195,005	215,482	212,183
Capital and reserves				
Called-up share capital	3	44,073	42,446	42,446
Share premium		26,840	20,036	20,036
Capital reserve		100,679	123,984	115,215
Revaluation reserve	5	19,933	25,715	30,853
Revenue reserve		3,480	3,301	3,633
Equity shareholders' funds		195,005	215,482	212,183
Net asset value per share		49.35p	55.07p	54.84p
Number of ordinary shares in circulation		395,120,875	391,292,410	386,878,657

Statement of cash flows

For the six months to 31 March 2025 (Unaudited)

	Six months to 31 March 2025 £'000	Six months to 31 March 2024 £'000	Year to 30 September 2024 £'000
Cash flows from operating activities			
Investment income received	1,069	949	1,963
Deposit interest received	4	17	38
Investment management fees paid	(1,981)	(1,758)	(3,523)
Other cash payments	(418)	(379)	(626)
Net cash outflow from operating activities	(1,326)	(1,171)	(2,148)
Cash flows from investing activities			
Purchases of investments	(13,072)	(19,526)	(34,994)
Disposals of investments	17,672	18,053	33,246
Net cash outflow from investing activities	4,600	(1,473)	(1,748)
Financing activities			
Gross proceeds of share issues	8,646	13,948	25,000
Gross proceeds from sale of shares from treasury	-	8	8
Gross cost of share buybacks	(4,037)	(1,114)	(4,007)
Costs of share issues	(271)	(1,075)	(1,075)
Costs of share buybacks	(18)	(20)	(31)
Equity dividends paid	(7,654)	(9,113)	(15,906)
Other costs charged to capital	(1)	(21)	(21)
Net cash (outflow)/inflow from financing activities	(3,335)	2,613	3,968
(Decrease)/increase in cash	(61)	(31)	72
Reconciliation of net cash flow to movement in net cash			
(Decrease)/increase in cash	(61)	(31)	72
Opening cash at bank and on deposit	752	680	680
Closing cash at bank and on deposit	691	649	752
Reconciliation of profit before taxation to net cash outflow from operating activities			
(Loss)/profit before taxation	(13,827)	7,424	13,295
Losses/(gains) on investments	13,492	(7,423)	(14,023)
Income reinvested	(667)	(986)	(1,322)
Increase in debtors	(61)	(315)	(255)
(Decrease)/increase in creditors	(263)	129	157
Net cash outflow from operating activities	(1,326)	(1,171)	(2,148)

Notes to the financial statements

For the six months to 31 March 2025 (Unaudited)

Basis of preparation 1

The condensed financial statements for the six months to 31 March 2025 comprise the unaudited financial statements set out on pages 15 to 18 together with the related notes on pages 19 to 22. The Company applies FRS 102 and the AIC SORP for its annual financial statements. The condensed financial statements for the six months to 31 March 2025 have therefore been prepared in accordance with FRS 104 'Interim Financial Reporting' and the principles of the AIC SORP. They have been prepared on a going concern basis. The financial statements have been prepared on the same basis as the accounting policies set out in the Company's Annual Report and Financial Statements for the year ended 30 September 2024.

The financial information contained in this half-yearly report does not constitute statutory accounts as defined in sections 434 – 436 of the Companies Act 2006. The half-yearly report for the six months ended 31 March 2025 and for the six months ended 31 March 2024 have been neither audited nor reviewed by the Company's Auditor. The information for the year to 30 September 2024 has been extracted from the latest published audited financial statements, which have been filed with the Registrar of Companies. The report of the Auditor for the audited financial statements for the year to 30 September 2024 was: (i) unqualified; (ii) did not include a reference to any matters to which the Auditor drew attention by way of emphasis without qualifying their report; and (iii) did not contain a statement under section 498 (2) or (3) of the Companies Act 2006. No statutory accounts in respect of any period after 30 September 2024 have been reported on by the Company's Auditor or delivered to the Registrar of Companies.

The Company's half yearly report has been made available on the Company's website (www.baronsmeadvcts.co.uk) and sent to shareholders where requested.

2 Performance and shareholder returns

Return per share is based on a weighted average of 387,160,562 ordinary shares in issue (31 March 2024 – 358,163,251 ordinary shares; 30 September 2024 - 373,425,403 ordinary shares).

Earnings for the first six months to 31 March 2025 should not be taken as a guide to the results of the full financial year to 30 September 2025.

3 Called-up share capital

Allotted, called-up and fully paid:

Ordinary shares

424,464,819 ordinary shares of 10p each listed at 30 September 16,271,660 ordinary shares of 10p each issued during the period 440,736,479 ordinary shares of 10p each listed at 31 March 2 37,586,162 ordinary shares of 10p each held in treasury at 30 S 8,029,442 ordinary shares of 10p each repurchased during the 45,615,604 ordinary shares of 10p each held in treasury at 3 395,120,875 ordinary shares of 10p each in circulation* at 31

* Carrying one vote each.

	£'000
er 2024	42,446
od	1,627
2025	44,073
September 2024	(3,758)
e period and held in treasury	(803)
31 March 2025	(4,561)
1 March 2025	39,512

During the six months to 31 March 2025, the Company issued 16,271,660 shares at net proceeds of £8,375,000 (after costs). During the same period, the Company purchased 8,029,442 shares to be held in treasury at a cost of £4,072,000. The Company sold no shares from treasury. At 31 March 2025 the Company held 45,615,604 ordinary shares in treasury. Shares may be sold out of treasury below Net Asset Value as long as the discount at issue is narrower than the average discount at which the shares were bought into treasury.

Excluding treasury shares, there were 395,120,875 ordinary shares in issue at 31 March 2025 (31 March 2024 – 391,292,410 ordinary shares; 30 September 2024 - 386,878,657 ordinary shares).

4 Dividends

The final dividend for the year ended 30 September 2024 of 2.00p per share (1.70p capital, 0.30p revenue) was paid on 17 March 2025 to shareholders on the register on 14 February 2025. The ex-dividend date was 13 February 2025.

During the year to 30 September 2024, the Company paid an interim dividend on 9 September 2024 of 1.75p per share (1.65p capital, 0.10p revenue).

An interim dividend of 1.75p per share has been declared for the year to 30 September 2025 and is payable on 8 September 2025 to shareholders on the register as of 8 August 2025. The ex dividend date is 7 August 2025.

Investments 5

All investments are initially recognised and subsequently measured at fair value. Changes in fair value are recognised in the Income Statement.

The methods of fair value measurement are classified into a hierarchy based on reliability of the information used to determine the valuation.

- Level 1 Fair value is measured based on quoted prices in an active market.
- Level 2 Fair value is measured based on directly observable current market prices or indirectly being derived from market prices.
- Level 3 Fair value is measured using a valuation technique that is not based on data from an observable market.

The valuation of unquoted investments contained within level 3 of the Fair Value hierarchy involves key assumptions dependent upon the valuation methodology used. The primary methodologies applied are:

- Cost of recent investment.
- Multiple basis.
- Offer less 10 per cent.

The multiple basis approach involves more subjective inputs than the cost of recent investment and offer approaches and therefore presents a greater risk of over or under estimation. Key assumptions for the multiple basis approach are the selection of comparable companies and the use of either historic or forecast revenue or earnings, as considered most appropriate. Other assumptions include the appropriateness of the discount magnitude applied for reduced liquidity and other qualitative factors. These assumptions are described in more detail in note 2.3 in the Company's Report and Financial Statements for the year to 30 September 2024. The techniques used in the valuation of unquoted investments have not changed materially since the date of that Report.

	Level 1	Lev	vel 2	Level 3	
	- · · ·		Collective		
	Traded on AIM £'000	Unquoted £'000	investment vehicles £'000	Unquoted £'000	Total £'000
Opening book cost	50,718	-	72,986	57,695	181,399
Opening unrealised appreciation/(depreciation)	15,248	-	22,074	(6,469)	30,853
Opening fair value	65,966	-	95,060	51,226	212,252
Movements in the period:					
Transfer between levels	(3,734)	1,230	-	2,504	-
Purchases at cost	619	-	10,147	2,973	13,739
Sale – proceeds	(220)	-	(17,428)	(24)	(17,672)
Sale – realised gains/(losses)	(80)	-	(342)	24	(398)
Unrealised (losses)/gains realised during the period	(2,561)	-	449	(62)	(2,174)
Decrease in unrealised appreciation	(1,658)	(829)	(4,802)	(3,631)	(10,920)
Closing fair value	58,332	401	83,084	53,010	194,827
Closing book cost	44,742	1,230	65,812	63,110	174,894
Closing unrealised appreciation/(depreciation)	13,590	(829)	17,272	(10,100)	19,933
Closing fair value	58,332	401	83,084	53,010	194,827
Equity shares	58,332	401	-	6,478	65,211
Preference shares	-	-	-	37,380	37,380
Loan notes	-	-	-	9,152	9,152
Collective investment vehicles	-	-	83,084	-	83,084
Closing fair value	58,332	401	83,084	53,010	194,827

In the 6 months ending 31 March 2025, two investments held, I-nexus Global plc and Merit Group plc previously Level 1 were transferred to Level 3 following their delistings from AIM.

One investment held, Scholium Group plc previously level 1 was transferred to level 2 as it is now being priced using JP Jenkins, a platform for trading unlisted assets, following its delisting from AIM.

Two investments held, Fulcrum Utility Services Ltd and LoopUp Group plc previously level 3 following their delistings from AIM were transferred to Level 2 as they are now being priced using JP Jenkins, a platform for trading unlisted assets.

Other required disclosures 6

6.1 Segmental reporting

The Company has one reportable segment being investing in primarily a portfolio of UK growth businesses, whether unquoted, traded on AIM or collective investment vehicles.

03 Financial Statements - Notes to the financial statements

6.2 Principal risks and uncertainties

The Company's financial instruments consist of equity and fixed interest investments, shares in collective investment schemes, cash balances and liquid resources. Its principal risks are therefore market risk, price risk, credit risk and liquidity risk. Other risks faced by the Company include loss of approval as a Venture Capital Trust, legislative, investment performance, economic, political and other external factors, regulatory and compliance and operational risks. These risks, and the way in which they are managed, are described in more detail in the principal risks and uncertainties table within the Strategic report section in the Company's Report and Financial Statements for the year to 30 September 2024. The Board continues to regularly review the risk environment in which the Company operates.

6.3 Related parties

Gresham House Asset Management Ltd (the "Manager") manages the investments of the Company. The Manager also provides or procures the provision of secretarial, administrative and custodian services to the Company. Under the management agreement, the Manager receives a fee of 2.0 per cent per annum of the net assets of the Company. This is described in more detail under the heading 'The management agreement' within the Strategic Report in the Company's Annual Report and Financial Statements for the year to 30 September 2024.

During the period, the Company incurred the following fees payable to the Manager:

	Six months to 31 March 2025 £'000	Six months to 31 March 2024 £'000	Year to 30 September 2024 £'000
Management fees	1,774	1,667	3,599
Secretarial and accounting fees Performance fees	83 –	83	164

The performance fee is described in more detail under the heading 'Performance fees' within the Strategic Report in the Company's Annual Report and Financial Statements for the year to 30 September 2024.

Under the terms of an Offer for Subscription, launched on 13 January 2025, the Manager was entitled to fees of 4.50% of the investment amount received from investors. This amount totalled £214,000 out of which all the costs associated with the allotments were met.

6.4 Going concern


After making enquiries, and bearing in mind the nature of the Company's business and assets, the Directors consider that the Company has adequate resources to continue in operational existence for the foreseeable future. In arriving at this conclusion, the Directors have considered the Company's cash balances, the liquidity of the Company's investments and the absence of any gearing. The Directors are therefore also satisfied that the Company has adequate financial resources to continue in operation for at least the next 12 months and that, accordingly, it is appropriate to adopt the going concern basis in preparing the financial statements.

6.5 Post balance sheet events

The following events occurred between the balance sheet date and the signing of these financial statements:

- The 30 April 2025 NAV of 50.1p was announced on 7 May 2025 and the 31 May 2025 NAV of 51.9p was announced on 5 June 2025. At the date of publishing this report, the Board is unaware of any matter that will have caused the NAV per share to have changed significantly since the latest NAV.
- Issued 21.8mn Ordinary Shares of 10.0p on 3 April 2025 at an average price of 53.6p per share.
- Issued 1.9mn Ordinary Shares of 10.0p on 1 May 2025 at an average price of 51.1p per share.
- Three new investments, into Penfold Technology, Spinners and Nu Quantum, completed between April and May 2025, totalling £2.9mn.
- One follow-on investment, into Airfinity, completed in April 2025, totalling £0.4mn.
- Totally plc announced on 6 June 2025 their intention to appoint administrators and requested a suspension of trading in the company's shares with immediate effect.





Cash returned to shareholders

The table below shows the cash and total returns to shareholders that invested in Baronsmead Venture Trust plc dependent on their subscription cost, including the income tax available to be reclaimed on the subscription.

Year subscribed	Cash invested (p)	Income tax reclaim (p)	Net cash invested (p)	Cumulative dividends paid [#] (p)	Return on cash invested (%)	Current NAV (p)	Total return (%)
1998 (Apr)	100.00	20.00	80.00	189.40	209.4	49.35	294.1
1999 (May)	102.00	20.40	81.60	185.90	202.3	49.35	275.3
2000 (Feb)	137.00	27.40	109.60	182.70	153.4	49.35	179.3
2000 (Mar)	130.00	26.00	104.00	182.70	160.5	49.35	192.8
2004 (Oct) – C Shares [‡]	100.00	40.00	60.00	137.70	177.7	49.35	174.6
2009 (Apr)	91.60	27.48	64.12	121.50	162.6	49.35	118.5
2012 (Dec)	111.80	33.54	78.26	96.00	115.9	49.35	48.7
2014 (Mar)	103.80	31.14	72.66	78.50	105.6	49.35	24.8
2016 (Feb)	102.80	30.84	71.96	64.00	92.3	49.35	11.6
2017 (Oct)	94.76	28.43	66.33	46.00	78.5	49.35	(0.2)
2019 (Feb)	84.20	25.26	58.94	39.50	76.9	49.35	4.3
2019 (Nov)	76.80	23.04	53.76	32.00	71.7	49.35	0.3
2020 (Jan)	82.40	24.72	57.68	32.00	68.8	49.35	(4.9)
2020 (Feb)	80.10	24.03	56.07	28.50	65.6	49.35	(0.4)
2020 (Mar)	63.80	19.14	44.66	28.50	74.7	49.35	12.9
2020 (Nov)	75.20	22.56	52.64	25.50	63.9	49.35	(4.8)
2020 (Dec)	78.00	23.40	54.60	25.50	62.7	49.35	(8.6)
2021 (Jan)	81.30	24.39	56.91	25.50	61.4	49.35	(9.9)
2021 (Feb)	78.80	23.64	55.16	22.00	57.9	49.35	(12.2)
2021 (Mar)	80.90	24.27	56.63	22.00	57.2	49.35	(14.3)
2021 (Dec)	83.10	24.93	58.17	19.00	52.9	49.35	(19.2)
2022 (Jan)	82.40	24.72	57.68	19.00	53.1	49.35	(16.9)
2022 (Mar)	72.60	21.78	50.82	15.50	51.3	49.35	(11.3)
2023 (Jan)*	64.25	19.28	44.97	12.50	49.5	49.35	(5.3)
2023 (Mar)*	62.64	18.79	43.85	9.75	45.6	49.35	(1.7)
2023 (Apr)*	60.26	18.08	42.18	9.75	46.2	49.35	(3.5)
2024 (Jan)*	58.78	17.63	41.15	8.00	43.6	49.35	(4.5)
2024 (Feb)*	58.29	17.49	40.80	5.50	39.4	49.35	(4.4)
2024 (Mar)*	58.01	17.40	40.61	5.50	39.5	49.35	(4.1)
2025 (Feb)*	53.13	15.94	37.19	1.75	33.3	49.35	(4.1)
2025 (Apr)*	53.57	16.07	37.50	1.75	33.3	49.35	_

[#] Includes interim dividend of 1.75p per share payable on 8 September 2025.

⁺ C Share dividend calculated using conversion ratio of 0.9657 which is the rate the C shares were converted into ordinary shares.

* Cash invested is the average effective offer price. Shares were allotted pursuant to the 2023, 2024 and 2025 Offers at individual prices for each investor in accordance with the allotment formula as set out in each Offer's Securities Notice.

Full investment portfolio

Company	Sector	Original book cost† £'000	Accounting book cost† £'000	31 March 2025 fair value £'000	30 September 2024 fair value £'000	% of net assets	% of equity held by Baronsmead Venture Trust plc	% of equity held by all funds#
Unquoted								
Patchworks Integration Ltd	Technology	5,063	5,063	6,369	6,233	3.3	10.2	24.3
Airfinity Ltd	Healthcare & education	3,911	3,911	4,863	4,894	2.5	8.6	20.1
Panthera Biopartners Ltd	Healthcare & education	3,081	3,081	4,377	3,699	2.2	11.3	26.7
Popsa Holdings Ltd	Technology	3,120	3,120	3,120	3,120	1.6	3.4	8.1
Scurri Web Services Ltd	Technology	2,033	2,033	2,595	2,499	1.3	6.1	14.7
Clarilis Ltd	Technology	1,679	1,679	2,514	2,514	1.3	7.0	16.7
Ozone Financial Technology Ltd	Technology	1,867	1,867	2,155	2,397	1.1	2.3	11.8
Fu3e Limited	Technology	1,680	1,680	2,048	1,981	1.1	12.6	29.7
TravelLocal Ltd	Consumer markets	1,879	1,879	1,878	1,879	1.0	4.7	10.9
Metrion Bioscience Ltd	Healthcare & education	1,543	1,543	1,816	1,772	0.9	11.1	26.8
Huddl Mobility Ltd (trading as CitySwift)	Technology	949	949	1,806	982	0.9	3.4	17.4
Huma Therapeutics Ltd	Healthcare & education	2,578	2,578	1,739	2,324	0.9	0.4	0.8
Counting Ltd	Business services	1,527	1,527	1,645	1,410	0.8	3.5	8.5
SecureCloud+ Ltd	Technology	1,170	1,170	1,535	1,495	0.8	7.9	16.7
Pointr Ltd	Technology	466	466	1,310	1,116	0.7	2.4	5.1
RevLifter Ltd	Technology	1,606	1,606	1,233	834	0.6	15.1	36.4
Focal Point Positioning Ltd	Technology	1,221	1,221	1,222	849	0.6	1.3	6.3
OnSecurity Technology Ltd	Technology	1,210	1,210	1,180	1,642	0.6	3.9	20.0
Proximity Insight Holdings Ltd	Technology	1,148	1,148	1,148	860	0.6	4.1	20.4
Branchspace Ltd	Technology	879	879	1,068	912	0.5	4.9	25.5
Gentianes Solutions Ltd (trading as Much Better Adventures)	Consumer markets	1,052	1,052	1,052	_	0.5	3.8	17.7
Cognassist UK Limited	Healthcare & education	896	896	1,046	1,008	0.5	4.4	22.2
SciLeads Limited	Technology	942	942	1,027	942	0.5	3.0	16.5
Lads Store Ltd (trading as Bidnamic)	Technology	949	949	944	944	0.5	1.9	9.1
Orri Ltd	Healthcare & education	1,608	1,608	905	1,572	0.5	14.3	63.5
Mobility Mojo (UK) Ltd	Technology	459	459	791	-	0.4	4.0	18.4
IWP Holdings Ltd	Business services	1,407	1,407	352	352	0.2	3.5	8.5
Mable Therapy Ltd	Healthcare & education	670	670	344	670	0.2	6.6	34.3
Connect Earth Ltd	Business services	447	447	336	336	0.2	2.9	14.7
Azarc.lo inc	Technology	659	659	165	329	0.1	4.5	23.1
Dayrize B.V.	Technology	917	917	160	229	0.1	5.9	31.3
Rockfish Group Ltd	Consumer markets	875	875	109	226	0.1	5.4	11.6
Custom Materials Ltd	Technology	2,530	2,530	-	-	0.0	12.4	27.6
Yappy Ltd	Consumer markets	2,009	2,009	-	120	0.0	18.9	40.4

Compony	Sector	Original book cost† £'000	Accounting book cost† £'000	31 March 2025 fair value £'000	30 September 2024 fair value £'000	E % of net assets	% of equity held by Baronsmead Venture Trust plc	% of equity held by all funds#
Company Unquoted (continued)	560101	£ 000	£ 000	£ 000	£ 000		ii ust pic	
Tribe Digital Holdings Ltd	Technology	1,198	1,198	_	_	0.0	5.4	11.5
Equipsme (Holdings) Ltd	Business services	842	842	_	_	0.0	5.7	12.1
SilkFred Ltd	Consumer markets	790	790	_	_	0.0	2.3	5.1
Knight Recruitment Group Ltd		705	705	_	_	0.0	9.8	23.8
CISIV Ltd	Technology	700	700	_	_	0.0	7.2	15.3
Munnypot Ltd	Technology	460	460	_	_	0.0	1.2	2.7
	rechnology	58,725	58,725	52,852		27.1	1.2	2.7
Delisted (previously AIM)		00,720	00,720	02,002		27.1		
Scholium Group plc	Consumer markets	900	626	396	288	0.2	6.6	14.7
LoopUp Group plc	Technology	504	504	4		0.0	0.2	0.6
Fulcrum Utility Services Ltd	Business Services	102	100	1	_	0.0	0.1	1.0
Merit Group plc	Technology	2.022	2,546	-	622	0.0	4.1	10.2
Crossword Cybersecurity plc	Technology	960	960	_	1,228	0.0	0.0	0.0
I-nexus Global plc	Technology	563	562	_	21	0.0	2.4	5.4
MXC Capital Ltd	Business Services	144	169	_	_	0.0	0.3	0.6
	Dusiness der vices	5,195	5,467	401		0.2	0.0	0.0
Total unquoted		63,920	64,192	53,253		27.3		
AIM		00,020	0.1102	001200				
Cerillion plc	Technology	879	879	17,648	20,639	9.1	3.9	8.7
Netcall plc	Technology	1,738	3,246	10,101	8,616	5.2	6.0	24.8
Property Franchise Group plc	Consumer markets	1,438	1,477	4,985	4,925	2.6	1.9	18.2
IDOX plc	Technology	614	614	3,715	3,881	1.9	1.4	6.9
Bioventix plc	Healthcare & education	253	669	2,313	3,662	1.2	1.8	12.2
Diaceutics plc	Healthcare & education	1,410	1,410	2,264	2,449	1.2	2.2	14.6
PCI-PAL plc	Technology	1,297	1,297	1,677	1,670	0.9	4.9	10.9
Anpario plc	Healthcare & education	304	768	1,650	1,474	0.8	2.2	6.8
Oberon Investments Group plc	Business services	1,519	1,519	1,485	939	0.8	4.7	9.9
Beeks Financial Cloud Group plc	Technology	337	337	1,417	1,647	0.7	1.0	2.2
IntelliAM AI plc	Technology	2,118	2,118	1,352	1,802	0.7	11.8	23.5
Begbies Traynor Group plc	Business services	433	474	1,069	1,063	0.5	0.7	3.8
Inspired plc	Business services	574	1,542	1,022	821	0.5	1.1	29.7
hVIVO plc	Healthcare & education	1,180	1,245	765	1,660	0.4	0.9	1.9
Skillcast Group plc	Healthcare & education	754	754	672	917	0.3	2.3	4.7
Tan Delta Systems plc	Business services	918	918	636	883	0.3	4.8	9.8
Pulsar Group plc	Business services	586	586	633	849	0.3	1.1	7.3
IXICO plc	Healthcare & education	1,148	1,148	592	217	0.3	8.0	17.7
Vianet Group plc	Business services	1,292	1,144	590	1,305	0.3	3.6	17.5
Eden Research plc	Business services	1,857	1,857	547	928	0.3	4.5	9.9
								14.7
								10.8
								24.5
SEEEN plc [‡] One Media iP Group plc Earnz plc	Technology Technology Business services	1,451 825 702	1,451 778 702	501 431 422	332 431 674	0.3 0.2 0.2	7.0 4.8 9.2	

04 Appendices - Full investment portfolio

SysGroup place Technology 1,292 1,310 394 684 0.2 2.5 26.2 Diales plac Business services 1,126 1,306 371 546 0.2 4.2 20.3 Everyman Media Group plac Consumer markets 782 825 349 528 0.2 1.0 9.6 Staffine Group plac Business services 174 4.614 216 202 0.1 0.9 1.8 Science In Sport plac Consumer markets 288 263 136 116 0.1 0.2 0.5 RMM22 plac Technology 592 592 108 247 0.0 3.0 6.4 Poolbeg Pharma plac Healthcare & education 540 39 27 0.0 0.6 1.4 Totaly plac Consumer markets 1.88 2.832 16 31 0.0 0.2 0.5 Rosslyn Data Technologies plac Technology 1.151 1.151 14 53 0.0 0.1 1.22 Rosslyn Data Technologies plac Technology <t< th=""><th>Company</th><th>Sector</th><th>Original book cost† £'000</th><th>Accounting book cost† £'000</th><th>31 March 2025 fair value £'000</th><th>30 September 2024 fair value £'000</th><th>% of net assets</th><th>% of equity held by Baronsmead Venture Trust plc</th><th>% of equity held by all funds#</th></t<>	Company	Sector	Original book cost† £'000	Accounting book cost† £'000	31 March 2025 fair value £'000	30 September 2024 fair value £'000	% of net assets	% of equity held by Baronsmead Venture Trust plc	% of equity held by all funds#
Diales pic Business services 1,126 1,306 371 546 0.2 4.2 20.3 Everyman Media Group pic Consumer markets 782 825 349 528 0.2 1.0 9.6 Staffline Group pic Business services 174 4.614 216 202 0.1 0.5 9.5 TPXimpact Holdings pic Technology 585 585 158 261 0.1 0.2 0.5 Science In Sport pic Consumer markets 288 263 136 116 0.1 0.2 0.5 RNM22 pic Technology 592 592 108 247 0.0 3.0 6.4 Poolbeg Pharma pic Healthcare & education 540 39 277 0.0 0.6 1.4 Totally pic Healthcare & education 70 170 177 36 0.0 0.2 0.5 Rosslyn Data Technologies pic Technology 1.151 14.5 53 0.0 0.1	AIM (continued)								
Everyman Media Group plc Consumer markets 782 825 349 528 0.2 1.0 9.6 Staffline Group plc Business services 174 4.614 216 202 0.1 0.5 9.5 TPXimpact Holdings plc Technology 585 585 158 261 0.1 0.9 1.8 Science In Sport plc Consumer markets 288 263 136 116 0.1 0.2 0.5 KRM22 plc Technology 450 450 112 144 0.1 1.3 2.8 Crimson Tide plc Technology 592 592 108 247 0.0 6.4 Poolbeg Pharma plc Healthcare & education 70 177 36 0.0 0.2 0.5 Tasty plc Consumer markets 1,188 2,832 16 31 0.0 1.4 10.2 Rosslyn Data Technologies plc Technology 7.88 4.42 9 35 0.0 0.1	SysGroup plc	Technology	1,292	1,310	394	684	0.2	2.5	26.2
Staffline Group pic Business services 174 4.614 216 202 0.1 0.5 9.5 TPXimpact Holdings pic Technology 585 585 158 261 0.1 0.9 1.8 Science In Sport pic Consumer markets 288 263 136 116 0.1 0.2 0.5 KRM22 pic Technology 592 592 108 247 0.0 3.0 6.4 Poolbeg Pharma pic Healthcare & education 44 44 53 188 0.0 0.4 0.9 Fusion Antibodies pic Healthcare & education 70 177 176 36 0.0 0.2 0.5 Tasty pic Consumer markets 1,188 2,832 16 31 0.0 1.4 10.2 Rosslyn Data Technologies pic Technology 7.88 442 9 35 0.0 0.1 0.2 Aptamer Group pic Technology 788 442 9 35 0.0 0.1 0.2 ColudCoco Group pic Technology 788 <td>Diales plc</td> <td>Business services</td> <td>1,126</td> <td>1,306</td> <td>371</td> <td>546</td> <td>0.2</td> <td>4.2</td> <td>20.3</td>	Diales plc	Business services	1,126	1,306	371	546	0.2	4.2	20.3
TPXimpact Holdings plc Technology 585 585 158 261 0.1 0.9 1.8 Science In Sport plc Consumer markets 288 263 136 116 0.1 0.2 0.5 KRM22 plc Technology 450 450 112 144 0.1 1.3 2.8 Crimson Tide plc Technology 592 592 108 247 0.0 3.0 6.4 Poolbeg Pharma plc Healthcare & education 540 39 27 0.0 0.6 1.4 Totally plc Healthcare & education 70 170 36 0.0 0.2 0.5 Tasty plc Consumer markets 1,18 2.832 16 31 0.0 0.4 1.02 Rosslyn Data Technologies plc Technology 1,151 144 53 0.0 0.01 0.2 Aptamer Group plc Technology 1,88 3.38 3 3 0.0 0.4 0.8 RUA Life Sciences plc Healthcare & education 5.09 2.8 3 3	Everyman Media Group plc	Consumer markets	782	825	349	528	0.2	1.0	9.6
Science in Sport pic Consumer markets 288 263 136 116 0.1 0.2 0.5 KRM22 pic Technology 450 450 112 144 0.1 1.3 2.8 Crimson Tide pic Technology 592 592 108 247 0.0 3.0 6.4 Poolbeg Pharma pic Healthcare & education 44 44 53 188 0.0 0.4 0.9 Fusion Antibodies pic Healthcare & education 70 170 17 36 0.0 0.2 0.5 Tasty pic Consumer markets 1,188 2,832 16 31 0.0 1.4 10.2 Rosslyn Data Technologies pic Technology 7.88 4.42 9 35 0.0 0.1 0.2 Aptamer Group pic Technology 788 4.42 9 35 0.0 0.0 0.0 CloudCoco Group pic Technology 438 338 3 3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	Staffline Group plc	Business services	174	4,614	216	202	0.1	0.5	9.5
KRM22 plc Technology 450 450 112 144 0.1 1.3 2.8 Crimson Tide plc Technology 592 592 108 247 0.0 3.0 6.4 Poolbeg Pharma plc Healthcare & education 44 44 53 188 0.0 0.4 0.9 Fusion Antibodies plc Healthcare & education 540 39 27 0.0 0.6 1.4 Totally plc Healthcare & education 70 177 36 0.0 0.2 0.5 Tasty plc Consumer markets 1,188 2,832 16 31 0.0 1.4 10.2 Rosslyn Data Technologies plc Technology 7,88 442 9 35 0.0 0.1 0.2 Aptamer Group plc Healthcare & education 2.00 2.206 5 4 0.0 0.1 0.2 CloudCoco Group plc Technology 438 338 3 3 0.0 0.0 0.0 Collective investment vehicle 66,850 44.890 58.490 30.0	TPXimpact Holdings plc	Technology	585	585	158	261	0.1	0.9	1.8
Crimson Tide plc Technology 592 592 108 247 0.0 3.0 6.4 Poolbeg Pharma plc Healthcare & education 44 44 53 188 0.0 0.4 0.9 Fusion Antibodies plc Healthcare & education 540 540 39 27 0.0 0.6 1.4 Totally plc Healthcare & education 70 170 17 36 0.0 0.2 0.5 Tasty plc Consumer markets 1,188 2,832 16 31 0.0 1.4 10.2 Rosslyn Data Technologies plc Technology 788 442 9 35 0.0 0.1 0.2 Aptamer Group plc Technology 788 442 9 35 0.0 0.1 0.2 Aptamer Group plc Technology 488 338 33 3 0.0 0.0 0.0 ColdcAcco Group plc Technology 488 338 3 3.9.60 15.4 WS Gresham House UK Micro Cap Fund 7,333 12,733 29,885 30,96	Science In Sport plc	Consumer markets	288	263	136	116	0.1	0.2	0.5
Prolibeg Pharma plc Healthcare & education 44 44 53 188 0.0 0.4 0.9 Fusion Antibodies plc Healthcare & education 540 540 39 27 0.0 0.6 1.4 Totally plc Healthcare & education 70 170 17 36 0.0 0.2 0.5 Tasty plc Consumer markets 1,188 2,832 16 31 0.0 1.4 10.2 Rosslyn Data Technologies plc Technology 1,151 1,151 14 53 0.0 0.0 1.4 Zoo Digital Group plc Technology 788 442 9 35 0.0 0.1 0.2 Aptamer Group plc Healthcare & education 2,06 5 4 0.0 0.1 0.2 CloudCoco Group plc Technology 438 338 3 3 0.0 0.0 0.0 Total AIM Selesham House UK Micro Cap Fund 7,333 12,733 29,885 30,960 15.4 WS Gresham House UK Multi Cap Income Fund 12,018 12,018	KRM22 plc	Technology	450	450	112	144	0.1	1.3	2.8
Fusion Antibodies plc Healthcare & education 540 540 39 27 0.0 0.6 1.4 Totally plc Healthcare & education 70 170 17 36 0.0 0.2 0.5 Tasty plc Consumer markets 1,188 2,832 16 31 0.0 1.4 10.2 Rosslyn Data Technologies plc Technology 1,151 1,151 14 53 0.0 0.6 1.4 Zoo Digital Group plc Technology 788 442 9 35 0.0 0.1 0.2 Aptamer Group plc Healthcare & education 2,206 2,206 5 4 0.0 0.1 0.2 CloudCoco Group plc Technology 438 338 3 0.0 0.4 0.8 RUA Life Sciences plc Healthcare & education 509 289 3 4 0.0 0.0 0.0 Collective investment vehicle Secences plc Healthcare & education 7,333 12,733 29,885 30,960 15.4 WS Gresham House UK Milti Cap Income Fund	Crimson Tide plc	Technology	592	592	108	247	0.0	3.0	6.4
Totally plc Healthcare & education 70 170 177 36 0.0 0.2 0.5 Tasty plc Consumer markets 1,188 2,832 16 31 0.0 1.4 10.2 Rosslyn Data Technologies plc Technology 1,151 1,151 14 53 0.0 0.6 1.4 Zoo Digital Group plc Technology 788 442 9 35 0.0 0.1 0.2 Aptamer Group plc Healthcare & education 2,206 2,206 5 4 0.0 0.0 0.0 CloudCoco Group plc Technology 438 338 3 0.0 0.4 0.8 RUA Life Sciences plc Healthcare & education 509 289 3 4 0.0 0.0 0.0 Total AIM 36,850 44,890 58,490 30.960 15.4 9 VS Gresham House UK Micro Cap Fund 7,333 12,733 29,885 30,960 15.4 WS Gresham House UK Multi Cap Income Fund 17,448 17,481 17,871 8,853 4.0 0 <td>Poolbeg Pharma plc</td> <td>Healthcare & education</td> <td>44</td> <td>44</td> <td>53</td> <td>188</td> <td>0.0</td> <td>0.4</td> <td>0.9</td>	Poolbeg Pharma plc	Healthcare & education	44	44	53	188	0.0	0.4	0.9
Tasty pic Consumer markets 1,188 2,832 16 31 0.0 1.4 10.2 Rosslyn Data Technologies pic Technology 1,151 1,151 14 53 0.0 0.6 1.4 Zoo Digital Group pic Technology 788 442 9 35 0.0 0.1 0.2 Aptamer Group pic Healthcare & education 2,206 5 4 0.0 0.1 0.2 CloudCoco Group pic Technology 438 338 3 0.0 0.4 0.8 RUA Life Sciences pic Healthcare & education 509 289 3 4 0.0 0.0 0.0 Total AIM 36,850 44,890 58,490 30,960 15.4 0.0 0.0 0.0 Collective investment vehicle 30,960 15.4 17,381 24,072 8.9 3.9 3.9 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 <td>Fusion Antibodies plc</td> <td>Healthcare & education</td> <td>540</td> <td>540</td> <td>39</td> <td>27</td> <td>0.0</td> <td>0.6</td> <td>1.4</td>	Fusion Antibodies plc	Healthcare & education	540	540	39	27	0.0	0.6	1.4
Rosslyn Data Technologies plc Technology1,1511,15114530.00.61.4Zoo Digital Group plcTechnology7884429350.00.10.2Aptamer Group plcHealthcare & education2,206540.00.10.2CloudCoco Group plcTechnology438338330.00.40.8RUA Life Sciences plcHealthcare & education509289340.00.00.0Total AIM36,85044,89058,49030,0615.4WS Gresham House UK Micro Cap Fund7,33312,73329,88530,96015.4WS Gresham House UK Smaller Companies Fund17,44817,44817,38124,0728.9WS Gresham House UK Multi Cap Income Fund12,01812,01812,20513,4696.3BlackRock Sterling Liquidity Fund7,8717,8717,8718,8534.0JPMorgan Sterling Liquidity Fund7,8717,8717,8718,8534.0JPMorgan Sterling Liquidity Fund7,8717,8717,8718,8534.0Total collective investment vehicle60,41265,81283,08442.6Total investments160,182174,894194,82799.9Net current assets178178,8940.11.4	Totally plc	Healthcare & education	70	170	17	36	0.0	0.2	0.5
Zoo Digital Group plc Technology 788 442 9 35 0.0 0.1 0.2 Aptamer Group plc Healthcare & education 2,206 2,206 5 4 0.0 0.1 0.2 CloudCoco Group plc Technology 438 338 3 3 0.0 0.4 0.8 RUA Life Sciences plc Healthcare & education 509 289 3 4 0.0 0.0 0.0 Total AIM 36,850 44,890 58,490 30.0 15.4 0.0 0.0 0.0 Collective investment vehicle WS Gresham House UK Micro Cap Fund 7,333 12,733 29,885 30,960 15.4 WS Gresham House UK Multi Cap Income Fund 17,448 17,381 24,072 8.9 WS Gresham House UK Multi Cap Income Fund 12,018 12,205 13,469 6.3 BlackRock Sterling Liquidity Fund 7,871 7,871 8,853 4.0 JPMorgan Sterling Liquidity Fund 7,871 7,871 8,853 4.0 JPMorgan Sterling Liquidity Fund 7,871 7,871 8,853 <td>Tasty plc</td> <td>Consumer markets</td> <td>1,188</td> <td>2,832</td> <td>16</td> <td>31</td> <td>0.0</td> <td>1.4</td> <td>10.2</td>	Tasty plc	Consumer markets	1,188	2,832	16	31	0.0	1.4	10.2
Aptamer Group plc Healthcare & education 2,206 2,206 5 4 0.0 0.1 0.2 CloudCoco Group plc Technology 438 338 33 3 0.0 0.4 0.8 RUA Life Sciences plc Healthcare & education 509 289 3 4 0.0 0.0 0.0 Total AIM 36,850 44,890 58,490 30.0 30.0 0.5 Collective investment vehicle 36,850 44,890 58,490 30.960 15.4 WS Gresham House UK Micro Cap Fund 7,333 12,733 29,885 30,960 15.4 WS Gresham House UK Multi Cap Income Fund 17,448 17,381 24,072 8.9 WS Gresham House UK Multi Cap Income Fund 12,018 12,205 13,469 6.3 BlackRock Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 JPMorgan Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 Total collective investment vehicle 60,412 65,812 83,084 42.6 42.6 Tot	Rosslyn Data Technologies p	Ic Technology	1,151	1,151	14	53	0.0	0.6	1.4
CloudCoco Group plc Technology 438 338 3 3 0.0 0.4 0.8 RUA Life Sciences plc Healthcare & education 509 289 3 4 0.0 0.0 0.0 Total AIM 36,850 44,890 58,490 30.0 0.0 0.0 0.0 Collective investment vehicle 36,850 44,890 58,490 30.0 15.4 WS Gresham House UK Micro Cap Fund 7,333 12,733 29,885 30,960 15.4 WS Gresham House UK Smaller Companies Fund 17,448 17,381 24,072 8.9 WS Gresham House UK Multi Cap Income Fund 12,018 12,205 13,469 6.3 BlackRock Sterling Liquidity Fund 7,871 7,871 8,853 4.0 JPMorgan Sterling Liquidity Fund 7,871 7,871 8,853 4.0 Total collective investment vehicle 60,412 65,812 83,084 42.6 Total investments 160,182 174,894 194,827 99.9 99.9	Zoo Digital Group plc	Technology	788	442	9	35	0.0	0.1	0.2
RUA Life Sciences plc Healthcare & education 509 289 3 4 0.0 0.0 0.0 Total AIM 36,850 44,890 58,490 30.0 30.0 30.0 Collective investment vehicle WS Gresham House UK Micro Cap Fund 7,333 12,733 29,885 30,960 15.4 WS Gresham House UK Smaller Companies Fund 17,448 17,381 24,072 8.9 4.00 1.00 1.00 WS Gresham House UK Multi Cap Income Fund 12,018 12,205 13,469 6.3 4.00 1.00 1.00 BlackRock Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.00 4.00 1.00 1.00 JPMorgan Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.00 1.00 1.00 Total collective investment vehicle 60,412 65,812 83,084 42.6 42.6 1.00 1.00 Net current assets 160,182 174,894 194,827 99.9 1.01 1.01	Aptamer Group plc	Healthcare & education	2,206	2,206	5	4	0.0	0.1	0.2
Total AIM 36,850 44,890 58,490 30.0 Collective investment vehicle 30.0 30.0 Collective investment vehicle 30.9 15.4 30.9 15.4 30.960 15.4	CloudCoco Group plc	Technology	438	338	3	3	0.0	0.4	0.8
Collective investment vehicle 7,333 12,733 29,885 30,960 15.4 WS Gresham House UK Smaller Companies Fund 17,448 17,448 17,381 24,072 8.9 WS Gresham House UK Multi Cap Income Fund 12,018 12,205 13,469 6.3 BlackRock Sterling Liquidity Fund 7,871 7,871 8,853 4.0 Goldman Sachs Sterling Liquidity Fund 7,871 7,871 8,853 4.0 JPMorgan Sterling Liquidity Fund 7,871 7,871 8,853 4.0 Total collective investment vehicle 60,412 65,812 83,084 42.6 Total investments 160,182 174,894 194,827 99.9 Net current assets 178 0.1	RUA Life Sciences plc	Healthcare & education	509	289	3	4	0.0	0.0	0.0
WS Gresham House UK Micro Cap Fund 7,333 12,733 29,885 30,960 15.4 WS Gresham House UK Smaller Companies Fund 17,448 17,448 17,381 24,072 8.9 WS Gresham House UK Multi Cap Income Fund 12,018 12,018 12,205 13,469 6.3 BlackRock Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 Goldman Sachs Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 JPMorgan Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 Total collective investment vehicle 60,412 65,812 83,084 42.6 Total investments 160,182 174,894 194,827 99.9 Net current assets 178 0.1	Total AIM		36,850	44,890	58,490		30.0		
WS Gresham House UK Smaller Companies Fund 17,448 17,448 17,381 24,072 8.9 WS Gresham House UK Multi Cap Income Fund 12,018 12,018 12,205 13,469 6.3 BlackRock Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 Goldman Sachs Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 JPMorgan Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 Total collective investment vehicle 60,412 65,812 83,084 42.6 Net current assets 160,182 174,894 194,827 99.9	Collective investment vehic	le							
WS Gresham House UK Multi Cap Income Fund 12,018 12,018 12,205 13,469 6.3 BlackRock Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 Goldman Sachs Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 JPMorgan Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 Total collective investment vehicle 60,412 65,812 83,084 42.6 Total investments 160,182 174,894 194,827 99.9 Net current assets 178 0.1	WS Gresham House UK Micro	o Cap Fund	7,333	12,733	29,885	30,960	15.4		
BlackRock Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 Goldman Sachs Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 JPMorgan Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 Total collective investment vehicle 60,412 65,812 83,084 42.6 Total investments 160,182 174,894 194,827 99.9 Net current assets 178 0.1 0.1	WS Gresham House UK Smal	ller Companies Fund	17,448	17,448	17,381	24,072	8.9		
Goldman Sachs Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 JPMorgan Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 Total collective investment vehicle 60,412 65,812 83,084 42.6 Total investments 160,182 174,894 194,827 99.9 Net current assets 178 0.1	WS Gresham House UK Multi Cap Income Fund		12,018	12,018	12,205	13,469	6.3		
JPMorgan Sterling Liquidity Fund 7,871 7,871 7,871 8,853 4.0 Total collective investment vehicle 60,412 65,812 83,084 42.6 Total investments 160,182 174,894 194,827 99.9 Net current assets 178 0.1	BlackRock Sterling Liquidity Fund		7,871	7,871	7,871	8,853	4.0		
Total collective investment vehicle 60,412 65,812 83,084 42.6 Total investments 160,182 174,894 194,827 99.9 Net current assets 178 0.1	Goldman Sachs Sterling Liquidity Fund		7,871	7,871	7,871	8,853	4.0		
Total investments 160,182 174,894 194,827 99.9 Net current assets 178 0.1	JPMorgan Sterling Liquidity Fund		7,871	7,871	7,871	8,853	4.0		
Net current assets 178 0.1	Total collective investment vehicle		60,412	65,812	83,084		42.6		
	Total investments		160,182	174,894	194,827		99.9		
Net assets 195,005 100	Net current assets				178		0.1		
	Net assets				195,005		100		

The original book cost column provides the combined cost of investments made by BVCT & BVCT2 prior to the merger of the two VCTs to become BVT. This is included for information purposes for shareholders reviewing the portfolio.

The accounting cost column ties into the investment note on page 21 of these accounts. For investments owned before the assets of BVCT were acquired by BVCT2 the accounting book cost is the sum of the original cost of the investment held in BVCT2 and the market value of the investment in BVCT at the date of the merger.

All funds managed by Gresham House Asset Management Ltd.

[±] Includes unquoted convertible loan note; Cost £148,000, Fair Value £158,000.

Glossary

AIM	The Alternative In Exchange, design the public market.
Annual Dividend Yield	The ratio of divide asset value per sh
Book Cost (Original)	Total acquisition v any disposals or c average cost basi
Book Cost (Accounting)	The original book in a subsequent tr
BVT	Baronsmead Vent
Collective Investment Vehicle	Includes WS Gres
Direct Investments	Investments held include investmer
Discount/Premium	If the share price i discount. The size the share price fro percentage of the per share, this situ
EBITDA	Earnings before In the cash flow gene that do not (yet) ge
IFA	Independent Final advice to their clie
Key Performance Indicators ("KPIs")	A measurable valu achieving core bu
NAV	The total value of a deducted all liabili
NAV per share	Total Net Asset Va
NAV total return	A measure showir of time, taking into to shareholders.
Return on Cash Invested to shareholders	The amount of cas cumulative dividen
Shares Held in Treasury	Shares in the Com freely traded shar
SME	Small and medium meet two of the th according to UK L
Total Assets	All assets, both cu owned by an entit
VCT Value	The value of an inv or any payment is
WS Gresham House Equity Funds	Includes WS Gres House UK Multi Ca Smaller Companie
80 per cent test	Ensuring that the investments in qu

nvestment Market, a sub-market of the London Stock ned to help smaller companies access capital from

end paid/declared for financial year divided by opening net hare.

value, including transaction costs, less the value of capitalised distributions allocated on a weighted sis.

cost of an asset, rebased to the value at which it was used ransaction, such as a transfer between entities.

iture Trust plc

sham House Equity Funds and cash liquidity funds.

I by the Baronsmead Venture Trust plc only. Does not nts held by WS Gresham House Equity Funds.

is lower than the NAV per share it is said to be trading at a e of the Company's discount is calculated by subtracting om the NAV per share and is usually expressed as a e NAV per share. If the share price is higher than the NAV uation is called a premium.

nterest, Tax, Depreciation and Amortisation – a proxy for nerated by a business, most commonly used for businesses generate operating or shareholder profits.

ancial Advisors, professionals who offer independent ents and recommend suitable financial products.

ue that demonstrates how effectively the Company is usiness objectives.

all the Company's assets, at current market value, having lities at their carrying value.

'alue divided by the number of shares.

ing how the Net Asset Value has performed over a period o account both capital returns and dividends paid

sh returned to shareholders through income tax reclaimed, and nds paid, expressed as a percentage of the initial investment.

mpany repurchased by itself, reducing the number of res.

m-sized entities. These are independent companies which hree recognition criteria for small or medium companies Legislation.

urrent and non-current. An asset is an economic resource ty that can lead to an increase in economic value.

vestment when acquired, rebased if the holding is added to s made which causes an increase or decrease in its value.

sham House UK Micro Cap Fund ("Micro Cap"), WS Gresham Cap Income Fund ("Multi Cap") and WS Gresham House UK ies Fund ("Small Cap").

Company meets the requirement to hold 80 per cent of its ualifying holdings.



Information

Shareholder information and contact details

Shareholder Account Queries

The Registrar for Baronsmead Venture Trust plc is The City Partnership (UK) Limited ("City").

City will deal with all of your queries with regard to your shareholder account, such as:

- Change of address
- Latest net asset value
- Your current shareholding balance
- Your payment history including any outstanding payments and reissue requests
- Your payment options (cheque, direct payment to your bank/building society account, reinvestment)
- Paper or electronic communications
- Request replacement share certificates (for which there may be additional administrative and other charges)

You can contact City with your queries in several ways:

Telephone: 01484 240 910

On-line:

Investor Hub https://gresham-house-vcts.cityhub.uk.com

Email:	registrars@city.uk.com
Post:	The City Partnership (UK) Limited The Mending Rooms, Park Valley Mills, Meltham Road, Lockwood, HD4 7BH

- Lines are open 9.00am to 5.30pm, Monday to Friday, excluding public holidays in England and Wales.
- Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the UK will be charged at the applicable international rate.
- City's secure website, Investor Hub, allows you to manage your own shareholding online.
- You will need to register to use this service on the Investor Hub.
- You should have your Access Token to hand, which is available on the Change in Registrar letter, any recently issued share certificate and dividend tax vouchers from City and which you should always keep confidential for security reasons. Should you not be able to locate this, City may provide it over the telephone following completion of a series of security questions.

The Company's Ordinary shares are listed on the London Stock Exchange (LSE). The LSE code for the Company is "BVT". Share price information can be obtained from the link on the Company's website and many financial websites.

Shares In Issue

As at 10 June 2025, the Company had 464,425,061 Ordinary shares of 10p each in issue which included 45,615,604 Ordinary shares of 10p each held in treasury. The total voting rights in the Company is therefore 418,809,457.

Calendar

August 2025	Quarterly factsheet to 30 June 2025
December 2025	Announcement of final results for the period to 30 September 2025
March 2026	Annual General Meeting

Additional information

The information provided in this report has been produced in order for shareholders to be informed of the activities of the Company during the period it covers. Gresham House Asset Management Ltd does not give investment advice and the naming of companies in this report is not a recommendation to deal in them.

Baronsmead Venture Trust plc is managed by Gresham House Asset Management Ltd which is authorised and regulated by the FCA. Past performance is not necessarily a guide to future performance. Stock markets and currency movements may cause the value of investments and the income from them to fall as well as rise and investors may not get back the amount they originally invested. Where investments are made in unquoted securities and smaller companies, their potential volatility may increase the risk to the value of, and the income from, the investment.

Secondary market in the shares of Baronsmead Venture Trust plc

The Company's shares can be bought and sold in the same way as any other quoted company on the London Stock Exchange through a stockbroker.

The market makers in the shares of Baronsmead Venture Trust plc are::

Panmure Liberum Limited	+44 (0)20 3100 2000 (the Company's broker)
Winterflood	+44 (0)20 3100 0000

Qualifying investors* who invest in the existing shares of the Company can benefit from:

- Tax free dividends;
- Realised gains are not subject to capital gains tax (although any realised losses are not allowable);
- No minimum holding period; and
- No need to include VCT dividends in annual tax returns.

The UK tax treatment of VCTs is on a first in first out basis and therefore tax advice should be obtained before shareholders dispose of their shares and also if they deferred a capital gain in respect of new shares acquired prior to 6 April 2004.

* UK income tax payers, aged 18 or over, who acquire no more than £200,000 worth of VCT shares in a tax year.

Warning to Shareholders

Many companies are aware that their shareholders have received unsolicited phone calls or correspondence concerning investment matters. These are typically from "brokers" based overseas who target UK shareholders offering to sell them what often turn out to be worthless or high risk shares in US or UK investments. They can be very persistent and extremely persuasive. Shareholders are therefore advised to be very wary of any unsolicited advice, offers to buy shares at a discount or offers for free company reports.

Please note that it is very unlikely that either the Company or the Company Registrar, City, would make unsolicited telephone calls to shareholders and that any such calls would relate only to official documentation already circulated to shareholders and never in respect of investment "advice".

If you are in any doubt about the veracity of an unsolicited phone call, please call either the Company or the Registrar at the numbers provided on page 34.

Protect Yourself

If you are offered unsolicited investment advice, discounted shares, a premium price for shares you own, or free company or research reports, you should take these steps before handing over any money or share certificates:

- 1. Get the name of the person and organisation contacting you.
- 2. Check the FCA Register at www.fca.org.uk/register to ensure they are authorised (or www.fca.org.uk/publication/systems-information/aifmd-small-register.pdf).
- 3. Use the details on the FCA Register to contact the firm.
- 4. Call the FCA Consumer Helpline on 0800 111 6768 (freephone) from 8.00am to 6.00pm, Monday to Friday (except public holidays) and 9.00am to 1.00pm, Saturday (from abroad call +44 20 7066 1000) if there are no contact details on the Register or you are told they are out of date.
- 5. Search the FCA's list of unauthorised firms and individuals to avoid doing business with.
- 6. REMEMBER: if it sounds too good to be true, it probably is!

If you use an unauthorised firm to buy or sell shares or other investments, you will not have access to the Financial Ombudsman Service (https://www.financial-ombudsman.org.uk/) or Financial Services Compensation Scheme (https://www.fscs.org.uk/) if things go wrong.

Report a Scam

If you are approached about a share scam you should tell the FCA using the Share Fraud Reporting Form

(www.fca.org.uk/consumers/report-scam-unauthorised-firm), where you can find out about the latest investment scams. You can also call the FCA Consumer Helpline on 0800 111 6768.

If you have already paid money (or otherwise dealt with share fraudsters) you should contact ActionFraud on 0300 123 2040 or use the ActionFraud (https://www.actionfraudalert.co.uk/) Online Reporting Tool.

More detailed information on this or similar activity can be found on the FCA web site.

Corporate information

Directors

Fiona Miller Smith (Chair)[†] Michael Probin^{††∆} David Melvin* (appointed 1 April 2025) Mandeep Singh (appointed 1 April 2025)

Secretary

Gresham House Asset Management Ltd

Registered Office

5 New Street Square London EC4A 3TW

Investment Manager

Gresham House Asset Management Ltd 5 New Street Square London EC4A 3TW Tel: 020 7382 0999

Registered Number

03504214

Registrars and Transfer Office

The City Partnership (UK) Ltd The Mending Rooms Park Valley Mills Meltham Road Lockwood HD4 7BH Tel: 01484 240 910

Brokers

Panmure Liberum Limited Ropemaker Place, Level 12 25 Ropemaker Street, London EC2Y 9LY Tel: 020 3100 2000

Auditor

BDO LLP 55 Baker Street London W1U 7EU

Solicitors

Howard Kennedy LLP 1 London Bridge London SE1 9BG

VCT Status Adviser

PricewaterhouseCoopers LLP 1 Embankment Place London WC2N 6RH

Website

www.baronsmeadvcts.co.uk

[†] Chair of the Nomination Committee

- ^{tt} Chair of the Management Engagement and Remuneration Committee
- △ Senior Independent Director
- * Chair of the Audit Committee

